Immuneering Reports 64% Overall Survival in First-Line Pancreatic Cancer Patients Using Atebimetinib
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company dedicated to improving cancer patient outcomes, has announced remarkable findings from its ongoing Phase 2a clinical trial. The study shows a 64% overall survival (OS) rate at 12 months among first-line pancreatic cancer patients treated with atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP). This significant milestone comes with over 13 months of median follow-up data and positions IMRX as a promising player in the oncology field.
Highlights of Overall Survival Data
The results indicate that the overall survival rate for patients receiving atebimetinib + mGnP nearly doubles the benchmark set by the standard treatment of gemcitabine/nab-paclitaxel (GnP). Key findings from the trial include:
- 64% overall survival at 12 months, contrasted with the 35%% OS reported in the pivotal MPACT trial.
- 83% OS at 9 months, compared to the standard of care’s approximate 47%% OS.
- 94% OS at 6 months, against the benchmark of 67%% OS.
Additionally, atebimetinib achieved a confirmed overall response rate (ORR) of 39%% and a disease control rate (DCR) of 81%% at 12 months, further underscoring its efficacy compared to GnP.
Future Clinical Trials and Milestones
Immuneering anticipates launching a pivotal Phase 3 clinical trial named MAPKeeper 301 in mid-2026, following alignment with regulatory bodies FDA and EMA. This trial will focus on overall survival as its primary endpoint, reinforcing the company’s commitment to bringing innovative treatments to market. IMRX plans several near-term milestones:
- Q2 2026: Present updated circulating tumor DNA data at a major scientific meeting.
- 1H 2026: Provide updated survival data from an expanded cohort of over 50 first-line pancreatic cancer patients.
- Mid-2026: Begin dosing the first patient in the pivotal Phase 3 trial of atebimetinib + mGnP.
- 2H 2026: Initiate dosing in a trial evaluating atebimetinib with Libtayo in non-small cell lung cancer.
Expert Commentary
Dr. Ben Zeskind, CEO of Immuneering, commented on these results, stating, “We are thrilled to report 64% overall survival at 12 months. The separation from the overall survival observed in standard care has been consistently strong at multiple time points.” Dr. Igor Matushansky, the company’s Chief Medical Officer, added, “These exceptional data underscore the potential of atebimetinib + mGnP to provide both significant OS and a favorable safety profile for our patients.”
Dr. Meredith Pelster, Associate Director at Sarah Cannon Research Institute, echoed this sentiment, noting, “The overall survival data for atebimetinib demonstrate its potential to be a better treatment option for patients with pancreatic cancer.”
Conference Call Information
Immuneering will host a conference call and live webcast at 4:30 p.m. ET on January 7, 2026, to discuss the latest findings and future directions. Interested participants can join the call by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 for international participants.